[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.40 -0.49% 81.20 80.40 82.20 83.80 80.40 83.00 309,522 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.1 369

Ekf Diagnostics Share Discussion Threads

Showing 3451 to 3475 of 3875 messages
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older
DateSubjectAuthorDiscuss
17/5/2021
09:36
To confirm why the above is worthy of note - It was previously announced by Myhealthchecked that the MyHealthChecked™ COVID-19 testing service will use the PrimeStore® MTM sample collection device supplied by EKF Diagnostic Holdings plc. The new Day 2 and Day 8 COVID-19 Travel Test Package also contains two PrimeStore MTM tubes (if you look closely enough) - hTTps://myhealthchecked.com/product/covid-19-travel-test-package/ So, it is likely that all the various test kits contain PrimeStore MTM, and it's likely that EKF assembles the various test kit packages too - hTTps://myhealthchecked.com/test-to-release/ Excerpt from the Chief Executive’s Review (Annual Report) - In what has been a year like no other I have been astounded at how my colleagues at EKF have been able to adapt to the pandemic, support a solid core business performance and introduce a new manufacturing capability from zero to a business that is now manufacturing hundreds of thousands of COVID-19 sample collection kits per annum. All the credit for this past 12 months has to go to the incredible employees at EKF in Wales, Germany and the US.
wan
17/5/2021
07:11
Worthy of note - MyHealthChecked PLC Additional Boots agreement for D2/D8 testing 17/05/2021 7:00am UK Regulatory (RNS & others) Additional Boots agreement for Day 2 & Day 8 testing Extends supply of COVID-19 testing services for international arrivals to the UK MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces it has on 16 May signed a second contract with Boots UK Limited ("Boots"), the health and beauty retailer and pharmacy group, to supply the MyHealthChecked(TM) COVID-19 at-home nasal swab kit, laboratory testing service and logistics for day two and day eight ("D2/D8") coronavirus testing for international arrivals. The contract with Boots for the D2/D8 testing service will run parallel, and be complementary, to the Company's pre-existing agreement, announced on 6 April 2021 . MyHealthChecked is currently the only at-home PCR testing kit provider within Boots for General Testing and Fit-to-Fly services, launched on 7 April, and now expands the offering within Boots to include D2/D8 tests that will be available to purchase online, via www.boots.com across the UK, from May 17. The MyHealthChecked(TM) COVID-19 testing kit allows customers to take a nasal swab themselves at home and send samples safely and securely via the Royal Mail Tracked 24 service to be tested using established laboratory-based PCR detection methods. D2/D8 testing is undertaken at the Manchester-based laboratories of MyHealthChecked and Yourgene Health plc (AIM: YGEN), with any sequencing required for positive day 2 samples that meet the DHSC sequencing criteria, undertaken at Yourgene Health plc. PCR results are provided to customers within 24-48 hours, via a secure online portal. The Agreement is on a non-exclusive basis and has an initial term of 12 months from 17 May 2021, with a one-month notice period for termination thereafter. The contract is expected to have a significant impact on the future performance of the MHC business and whilst volumes are unquantified at this stage, the Board believes it is likely to result in substantial revenue growth in the current financial year ending 31 December 2021. MyHealthChecked(TM) also offers the testing kits online via www.myhealthchecked.com . Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "This is another milestone for MyHealthChecked as currently Boots' only at-home testing kit provider for COVID-19, and we are delighted to build on our pre-existing agreement as the nation begins to open up and we anticipate the possibility of travel with the introduction of the traffic light system. The D2/D8 contract is a testament to the service that MyHealthChecked provides as we pride ourselves on the quality and accuracy of our tests, as well as our operations and customer service. "We look forward to continuing our partnership with Boots and while it is still in its infancy, we hope to update the market imminently as we deliver on this contract." Full release - hTTps://uk.advfn.com/stock-market/london/myhealthchecked-MHC/share-news/MyHealthChecked-PLC-Additional-Boots-agreement-for/85121129
wan
14/5/2021
16:28
From December - the facts: https://www.investegate.co.uk/ekf-diagnostics-hldg--ekf-/rns/approval-of-dividend-in-specie/202012140700084652I/ On 11 December 2020 the board of EKF (the "Board") convened and declared a dividend in specie of shares in Trellus to trustees, to be held on trust for the Company's shareholders (the "Dividend"). EKF's investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share"). The Golden Share is the voting share in the capital of Trellus and will be retained by the Company. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company. Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited ("Broadway"), at which time an 'omnibus' share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of: · 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or · if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the "Lock-up Period"). During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares. The A Shares and the Golden Share will, on the earlier of the admission to trading of Trellus on AIM (or another recognised stock exchange) and two years from the date that the Dividend is settled, automatically convert into ordinary shares in Trellus ("Ordinary Shares") on the basis of one Ordinary Share for each A Share or Golden Share held. If Trellus is admitted to trading on AIM (or another recognised stock exchange), the Lock-up Period will continue to apply to the converted Ordinary Shares. All converted Ordinary Shares will rank equally in all respects with all other Ordinary Shares including in respect of voting and dividend rights. The legal title to the Dividend Shares will be held by Broadway as trustee, during the Lock-Up Period. If the A Shares are converted into Ordinary Shares during the Lock-up Period, Broadway will request that Trellus' registrar seeks the voting instructions of the Relevant EKF Shareholders in relation to any shareholder resolution of Trellus and will vote those Dividend Shares in accordance with such instructions as it receives . At the end of the Lock-up Period, Broadway will execute stock transfer forms to transfer the Dividend Shares to the Relevant EKF Shareholders based on a schedule provided by the Company's registrar. Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway. Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Dividend Shares. The anticipated timetable for the Dividend is: EKF ordinary shares marked as ex rights Start of trading on 16 December 2020 Record date for the distribution of the Dividend Close of business on 17 December 2020 Transfer of shares in Trellus to Broadway as trustee 18 December 2020 The undertaking in relation to Broadway acting as legal holder of the Dividend Shares can be accessed via the investor section of the Company's website.
mirandaj
14/5/2021
15:38
Is Trellis the same as Verici, where even though the stock shows in your account you can't trade until quite some months after the ipo?
cisk
14/5/2021
15:05
Thanks. CD
cambridgedon
14/5/2021
14:28
It's my understanding that we are currently in a lock-up while we await the IPO, the transfer of the shares into holders' accounts and the AIM listing. Shareholders will be able to sell on the day of admission (28 May) as I understand it, in theory at least. Though this might not be the case for many as accounts may not be updated in time to permit trading on the first day of admission.
jacks13
14/5/2021
13:38
Please can someone remind me of the lock up conditions applicable to Trellus Health? Also, when can we expect to see the shares in our trading accounts now the AIM admission date is announced as 28th May. Thanks, CD
cambridgedon
14/5/2021
12:06
Trellus was in the price* up until the distribution of EKF's shareholding. Or more precisely, until the in-specie distribution went ex-dividend back in December. ' ...In December, the Company transferred this shareholding to its then shareholders by way of a dividend in specie. It is expected that Trellus will complete an IPO in 2021.' rns 30 March *Whether or not Trellus was 'for free' is semantics. Maybe no value had been recognised in previous EKF accounts.
jacks13
14/5/2021
11:50
wan... I did listen to the interview... ...or rather the Chris Mills monologue. My apologies for missing the comment re Trellus.
shanklin
14/5/2021
11:42
Shanklin...Not according to Chris Mills (if you listened to the interview) where he said "Trellus was in the price for free" Rivaldo...Thanks for the heads-up.
wan
14/5/2021
11:17
wan So the 64p/share included Trellus Health?
shanklin
14/5/2021
11:11
Share price failing to oblige gents - Mr Market has a logic different to "house" brokers. A close below 58 and (if it happens of course) and and we will be on a sailing trip South of Atlantic.
tongosti
14/5/2021
10:49
RNS just out confirming Trellus Health to float on AIM on 28th May, with N+1 Singer as broker and Nomad: Https://www.investegate.co.uk/aim/rns/schedule-one---trellus-health-plc/202105141030026859Y/ "On 20 August 2020, EKF Diagnostics Holdings plc (EKF) announced that it had led, in partnership with ISMMS, a $5 million strategic investment into the Company. On 18 December 2020, EKF distributed its investment in the Company to EKF shareholders on its register at that time, by way of a dividend in specie of its entire holding of 27,999,999 non-voting Trellus A Shares. Transfer of these shares took place on 18 December 2020 to Broadway Nominees Limited to be held on trust for the underlying EKF shareholders. On Admission, all A Shares will convert to Ordinary Shares."
rivaldo
14/5/2021
09:49
Edit - Interview link added to above post.
wan
14/5/2021
09:42
I decided I would remind myself what Chris Mills said in an interview on the 17th November 2020 regarding EKF when the share price was 64p. In short, there were a number of elements he regarded as being in the price for free at 64p, albeit he did state at some point they would have to sell some shares, as EKF would be too big a percentage of their portfolio, "but it sure ain't at this price" (64p). He also said EKF had "life way beyond COVID". Interview (EKF at 15mins 40 seconds in) hTTps://www.voxmarkets.co.uk/media/5fb3dd97bc74c922485f4f5b/ So, as discussed on here, we probably know why Chris Mills sold some at 80p, but given his remarks regarding the price at 64p, investors will no doubt be wondering where the floor is. So, it will thus be interesting to see if we are there yet, but it is perhaps worth recalling that the directors are incentivised in the event that the Company is acquired by a third party. However, clearly Chris Mills expects more that 64p for their EKF shares, believing there are elements included in the price for free and plenty of growth to go for too beyond COVID, which apparently we will be updated on. An exit is not something I would normally highlight, nor indeed promote ("not at this price"), but there is currently a lot of M&A in our sector. To be clear, an exit is currently not what I am wishing for though, but I do wonder whether some form of change is afoot. Currently, I see more reasons to buy than sell, but investors should of course make up their own minds when making investment decisions etc.
wan
14/5/2021
09:11
This is a fan club as you may have noticed. Wait for someone to come back to you here telling you that nothing has changed / price moves are just nonsense etc etc. Seriously - an attempt to fail off previous highs raises serious questions. Folks forget we make money if and only if the market agrees with us. It happens far less frequently than most o would have one believe.
tongosti
14/5/2021
08:23
Directors selling, price collapsing, what's going on here ??
wanttowin
13/5/2021
09:11
I should have perhaps added to the above that the EKF/Longhorn sample collection media/devices are not specifically limited to collecting, inactivating/preserving COVID-19, and are applicable to other (new and existing) highly infectious diseases. A long a shelf life independent of refrigeration (up to 2 years), is another attribute (which also happens to dovetail rather well with home testing kits). Thus, having the the ability to respond to new and existing virus outbreaks via rapid access to substantial sample collection stocks, and indeed having the appropriate manufacturing capacity, will also be strategically important factors in meeting future preparedness.
wan
13/5/2021
07:52
All eyes appears to be on the volume of COVID-19 testing (and inflation), but most of us appreciate EKF is about more than COVID testing, and if the Times journalist is correct, it would appear EKF will be updating us soon in this regard. The virus is still circulating, albeit vaccines are thankfully having an effect. But the threat from variants appears very real, which can only be identified and observed by testing and will require the continued deployment of surge testing. As an aside to the above and food for thought, through the NHS, recently I had to take a COVID pcr test and isolate for three days prior to a small procedure, will this be the new normal? Whilst all eyes are fixated on testing volumes, I have not seen much about preparedness. The following recent articles though, caught my attention - Global health system ‘unfit’ for purpose and major reform needed, concludes independent review By Paul Nuki, GLOBAL HEALTH SECURITY EDITOR, LONDON and Sarah Newey, GLOBAL HEALTH SECURITY CORRESPONDENT 12 May 2021 • 11:00am In the presentation of the report and its findings to the press, former President Sirleaf stressed the need for bold reform. “Our message is simple and clear: the current system failed to protect us from the Covid-19 pandemic. And if we do not act to change it now, it will not protect us from the next pandemic threat, which could happen at any time.” The report added that the world was repeatedly warned about the potential threat of a pandemic ahead of the Covid-19 outbreak but had failed to act. Greater investment is also seen as crucial, now and in the future. The report calls on the G7, currently led by the UK and set to meet in Cornwall next month, to “immediately commit” to provide 60 per cent of the US$19 billion required in 2021 for vaccines, diagnostics and therapeutics to fight Covid-19. In the longer term, the report calls for the creation of an International Pandemic Financing Facility, which would have the capacity to mobilize long term (10-15 year) contributions of approximately US$5-10 billion a year to finance ongoing readiness globally. The idea is to build a global contingency fund so US$50-100 billion could be disbursed at short notice in the event of a new outbreak. The Global Health Threats Council would allocate and monitor the funding to institutions which have the capacity to support the development of preparedness and response capacities. “Heads of state and government should at a global summit adopt a political declaration under the auspices of the UN General Assembly to commit to these transformative reforms”, it adds. Full story - hTTps://www.telegraph.co.uk/global-health/science-and-disease/chernobyl-moment-global-health-system-unfit-purpose-major-reform/ Press Release New York, NY (May 06, 2021) Biopreparedness Expert Gustavo Palacios, PhD, to Join Mount Sinai, Strengthening Research Collaborations with Department of Defense “I am delighted to welcome Dr. Palacios to our team as we continue to lead a national effort to understand new and emerging viruses and thwart future pandemics,” said Dr. Palese. “The globe has felt the devastation of the recent pandemics, which highlight the need to invest in research and development to end the current crisis and the next one in waiting. Public, private, government, and academic efforts are crucial to create a biopreparedness system for the country and the globe. We are excited to further strengthen our ties with government researchers and scientists who share a common goal of protecting public health.” Mount Sinai Health System is uniquely positioned to become a biosurveillance network to detect emerging pathogens and evaluate medical countermeasures and diagnostic devices to allow rapid response. During outbreaks of emerging infectious diseases, the ability to collect specimens is crucial. Clinical samples are needed to determine baseline levels of host and pathogen biomarkers, as well as for determining clinical sensitivity and specificity values to inform diagnostic test development and refinement. The outbreak of SARS-CoV-2, the virus that causes COVID-19, during 2020 and West Nile virus in 1999 demonstrate the huge impact of travel and movement of goods in the introduction of emerging pathogens through New York City. The unique collaboration between Mount Sinai, the U.S. Army, and DoD is paramount to prepare for future events. “To efficiently and effectively counter an epidemic caused by a known or unknown pathogen, deliberate and advanced research expertise, planning, and development are crucial for a rapid and strategic response. Our government and industry partners enable the accelerated development of medical countermeasures and global defense. The collaboration between USAMRIID and Mount Sinai will enhance the world’s capabilities for an integrated response to the current and future global pandemics,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs at Mount Sinai Health System. Full release - hTTps://www.mountsinai.org/about/newsroom/2021/biopreparedness-expert-gustavo-palacios-phd-to-join-mount-sinai-strengthening-research-collaborations-with-department-of-defense
wan
12/5/2021
16:13
Someone the other day branded this down price action as noise. Am sure you all are filing up your boots today. Hang on - where's the excitement? Lol.
tongosti
12/5/2021
14:59
Chris - any comment on the share price dear? Lol.
tongosti
11/5/2021
07:40
I have so far resisted the temptation to filter Mr Market I too don't post much and exclusively on shares where I have an interest I feel I have a duty to novice investors to call out fathead like Mr Market
chris16041
10/5/2021
21:59
Lol - suprisingly I'm not a big poster on ADVFN these days - i have a very clear on how I trade/invest these days and opinions don't sway me - I just drop by for the odd bit of sport lol
davr0s
10/5/2021
20:48
DavROs - please do what most of us here do and filter her/him. If you reply you will just provoke another post and waste the time of the rest of us. My board said there were 7 new posts here so I opened this thread only to find 4 filtered posts and 3 replies from you.
sharw
10/5/2021
14:20
Preaching to the converted. I have given up on predicting a long time ago (learned the hard way). Bending with the market is my game. And that inevitably leads one to assessing probabilities and sharpen tape reading skills. If and when this breaks out properly I will na back on the train like I once was. Until then I'd rather wait. Patiently.
tongosti
Chat Pages: Latest  143  142  141  140  139  138  137  136  135  134  133  132  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210925 19:45:09